With more than 170 years of history and research, Pfizer is more than ever an innovative biopharmaceutical company. It specialises in cutting-edge research to improve the lives of patients around the world through increasingly targeted treatments.
Pfizer develops new medicines through the strength of its research teams and innovation programmes. Nearly 100 compounds are currently in development or under evaluation by the authorities. This dynamic is at the heart of our business and requires significant investment: Pfizer devotes 15% of its turnover to Research and Development.
Belgium is a particularly important country for the Pfizer Group, as it hosts almost the entire drug development and manufacturing process, from clinical research to distribution management, at various sites in the country.